Overview

Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy

Status:
Completed
Trial end date:
2020-02-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) from matched sibling donor (MSD),matched unrelated donor (MUD) and haploidentical related donors(HRD) in the treatment of hematologic malignancy.
Phase:
N/A
Details
Lead Sponsor:
Nanfang Hospital of Southern Medical University
Collaborators:
First Affiliated Hospital of Guangxi Medical University
Fujian Medical University
Fujian Medical University Union Hospital
Guangdong General Hospital
Guangdong Provincial People's Hospital
Guangxi Medical University
Guangzhou First Municipal People’s Hospital
Guangzhou First People's Hospital
Guangzhou General Hospital of Guangzhou Military Command
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Third Affiliated Hospital, Sun Yat-Sen University
Tongji Hospital
Wuhan Union Hospital, China
Xiangya Hospital of Central South University
Zhujiang Hospital
Treatments:
Antilymphocyte Serum
Cyclosporine
Cyclosporins
Methotrexate
Mycophenolate mofetil
Mycophenolic Acid